The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Sarilumab Is Effective for RA, Pregabalin Fails to Meet Study Endpoint & Ibuprofen Can Be Administered with a Patch

Sarilumab Is Effective for RA, Pregabalin Fails to Meet Study Endpoint & Ibuprofen Can Be Administered with a Patch

January 13, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Sarilumab Effective for RA
Sarilumab is a human monoclonal antibody directed against the IL-6 receptor. In the TARGET RCT trial, sarilumab, in combination with non-biologic disease-modifying anti-rheumatic drugs (DMARDs), demonstrated efficacy in patients with active rheumatoid arthritis (RA).1 This was an intent-to-treat population (n=546). Patients were randomized in a 1:1:1 ratio to receive placebo, 150 mg sarilumab every two weeks or 200 mg sarilumab every two weeks with background DMARDs. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), AM stiffness, Pain VAS, Work Productivity Survey, Rheumatoid Arthritis Impact of Disease and Short Form-36 (SF-36) were the patient-reported outcomes assessed.

You Might Also Like
  • Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis
  • Sarilumab Approval Stalled; Piclidenoson Promising for Psoriasis
  • Can IL-6 Predict Sarilumab Response?
Also By This Author
  • Medication Adherence for Osteoporosis Prevention

Patients were evaluated at baseline and Weeks 2, 4, 12 and 24. Baseline evaluation showed all patients had a significant disease burden. For sarilumab-treated patients, statistically significant improvements (P<0.025) were seen compared with placebo-treated patients for FACIT-F, AM stiffness, pain, Work Productivity Survey and Rheumatoid Arthritis Impact of Disease. The Physical Component Summary Measure of the SF-36 also significantly improved, with no decline in the SF-36 Mental Component Summary Measure. Significant improvements were seen in the majority of the SF-36 domain scores for sarilumab-treated patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Serious adverse events and treatment emergent adverse events occurred more commonly in sarilumab-treated patients than in placebo-treated patients. Laboratory findings were consistent with IL-6 blockade and from observations reported from the prior MOBILITY study. From the RA patient perspective, ability to participate in family and leisure activities, fatigue, morning stiffness, pain and being able to work were important outcomes to assess treatment effectiveness. The achievement of these outcomes was demonstrated in this study.

Pregabalin Fails in Clinical Trial
In a recent Phase 3 study, pregabalin (Lyrica) missed its primary efficacy endpoint for mean pain reduction from baseline compared with placebo in adults with chronic post-traumatic peripheral neuropathic pain.2 This 15-week study evaluated pregabalin treatment using daily pain diaries kept by patients to report their pain scores. No new safety signals were identified. The most common adverse events were dizziness, fatigue, nausea and somnolence.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Ibuprofen in a Patch
Working in conjunction with the polymer technology company, Medherant, researchers at the University of Warwick in England have developed a patch that delivers a consistent dosage of ibuprofen transdermally.3 The patch, a transparent adhesive, delivers a prolonged, transdermal, high dosage of ibuprofen over 12 hours. This product does a better job of controlling the dosage than other topical ibuprofen products—none of which are available in the U.S., but are available abroad. The patch is cosmetically appealing and transparent, and has a strong adhesive that remains in place throughout its use. It’s also comfortable and easy to remove.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Biologics & Biosimilars, Drug Updates Tagged With: Pain, peripheral neuropathic pain, pregabalin, Rheumatoid Arthritis (RA), sarilumab

You Might Also Like:
  • Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis
  • Sarilumab Approval Stalled; Piclidenoson Promising for Psoriasis
  • Can IL-6 Predict Sarilumab Response?
  • Ibuprofen an Option for Early Pain Control after Hip Replacement

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)